PK and Safety of CKD-333 vs Co-administration of CKD-330 and D086 in Healthy Volunteers

Phase 1, randomised, open-label trial of candesartan cilexetil, amlodipine and atorvastatin in hypertension (HTN) and dyslipidemia, sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve to the last quantifiable concentration at 72 hours and Maximum Plasma Concentration at 72 hours. Status: unknown.